Novartis Looks To Expand Beovu’s Use And Move On From Safety Scare
Diabetic Macular Edema (DME) Filing Possible In 2021
New data for a further indication should help Novartis rebuild momentum for competitor to Eylea, but safety concerns could take years to overcome.
You may also be interested in...
TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.